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1063-66 Arterial Closure Device Decreases Vascular 
Complications After Percutaneous Coronary 
Interventions
Michael C. Kim, Annapoorna S. Kini, Paul C. Lee, Marybeth Duffy, Thomas Joseph, 
Warren Sherman, Samin K. Sharma, Mount Sinai School of Medicine, New York, NY
Background: Vascular complication is an important determinant of patient satisfaction
after Percutaneous Coronary Interevntion (PCI). Many studies have shown that use of
closure devices (CD) had lower vascular complications after PCI , but some studies have
not.
Methods: We analyzed patients who had PCI from July 1999 to March 2003: 2,033
patients had attempted closure devices (61% Perclose, 27% Angioseal, 6% Vasoseal,
3% Duett, 2% unsuccessful), and 4,419 patients had manual compression.
Results: Using intention to treat analysis, the use of closure device compared to manual
compression (MC) resulted in decrease in overall vascular complication (1.4% vs. 2.6%,
p=0.0008): specifically, in moderate to large hematomas, or retroperitoneal bleeding
(p=0.0062), pseudoaneurysm (p=0.003), but not in vascular surgery (p=0.7)). Successful
deployment of the device had a very low vascular complication rate (1.2%). The predic-
tors for CD deployment failure(2% of all devices used) were: Month of July (8.4% vs.
1.7% p<0.0001) and increasing body weight (p=0.03). After successful deployment of
CD, the predictors for significant vascular complications included July month, the use of
Duett or Vasoseal (7.7% vs. 1.1% in Perclose or Angioseal, p<0.0001), female sex (2.2%
vs. 0.8%, p<0.0001), CHF NYHA class (p=0.0034), age (p<0.001), and the use of post-
procedural heparin (3.4% vs. 1.1% p=0.04), but not the use of glycoprotein IIb/IIIa
(p=0.8). Weight and ACTmax were not predictors for vascular complication after suc-
cessful deployment of device. If the device fails to deploy, the risk of vascular complica-
tion was much higher (18% vs. 1.2%, p<0.0001), especially if glycoprotein IIb/IIIa had
been used (21% vs. 0%, p=0.04), mostly moderate or large hematoma. Vascular compli-
cation was a significant predictor for in-hospital death (p<0.0001), though the successful
or unsuccessful use of CD had no significant statistical impact on survival. Length of stay
was significantly lower in CD (1.9±3.1 day vs. 2.6±5.0 days) p<0.0001).
Conclusion: Use of vascular closure devices after PCI resulted in significantly lower vas-
cular complications and a significantly lower length of stay.
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803-1 The Number and Adhesive Properties of Circulating 
Endothelial Progenitor Cells in Patients With In-Stent 
Restenosis
Hylton I. Miller, Jacob George, Itzhak Herz, Emil Goldstein, Solicu Abshizada, Arik 
Finkelstein, Yoav Michowitz, Gad Keren, Tel-Aviv Medical Center, Tel-Aviv, Israel
Background: Endothelialization is essential to facilitate vessel healing after stent deploy-
ment to prevent restenosis. Circulating endothelial progenitor cells (EPC) are present in
the peripheral blood and display endothelial functional properties along with ability to
home to damaged vasculature. Prolific in-stent intimal growth may be related to impaired
endothelialization resulting from a reduced number or dysfunction of circulating EPC.
Methods: 27 patients (pts) after stent deployment had recurrent unstable angina and
underwent coronary angiography. In 16 pts in-stent restenosis was demonstrated (group
A), in 6 focal and in 10 diffuse. 11 had patent stents (group B). Both groups were similar
with respect to drug usage and risk factors. Circulating EPC numbers were determined
by the colony-forming unit assay and their phenotype was characterized by endothelial-
cell markers. Adhesiveness of EPC from both groups to extra-cellular matrix and to
endothelial cells was also assayed.
Results: Pts in both groups with in-stent restenosis and with patent stents displayed a
similar number of circulating EPC (26.5±2.6 vs. 25.3±4.8). Pts with diffuse in-stent rest-
enosis exhibited reduced numbers of EPC (24.0±3.9) as compared with patients with
focal restenosis (30.7±1.7; p<0.05). Fibronectin-binding was compromised in pts in group
A as compared to pts of group B (9.2±2.5 vs. 15.3±3.2 cells/field; p<0.01
Conclusions: Reduced numbers of circulating EPC in pts with diffuse in-stent restenosis
and impaired adhesion of EPC from patients with restenosis provides a potential mecha-
nism mediating the exuberant proliferative process of restenosis. These markers, if fur-
ther validated, could provide means of risk stratifying patients for the likelihood of
developing in-stent restenosis.
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803-2 Genetic Predictive Factors for Restenosis After 
Percutaneous Transluminal Coronary Angioplasty
Pascalle S. Monraats, Willem R.P Agema, Aeilko H. Zwinderman, Robbert J. de Winter, 
Rene A. Tio, Pieter A.F.M Doevendans, Harry J.G.M Crijns, Moniek P.M de Maat, Douwe 
E. Atsma, Arnoud van der Laarse, Ernst E. van der Wall, J.Wouter Jukema, Leiden 
University Medical Center, Leiden, The Netherlands
Background: Percutaneous transluminal coronary angioplasty (PTCA) is still limited by
the recurrence of luminal stenosis. The underlying mechanisms are not fully understood.
Stratifying patients at risk based upon clinical factors has proven difficult so far. However
evidence exists that gene polymorphisms may play a role in the restenotic process. The
aim of this study was to evaluate if various gene polymorphisms can predict clinically
important restenosis after PTCAin an unselected patient population and thereby influ-
ence the choice of therapy.
Methods: The GEnetic DEterminants of Restenosis (GENDER) project was a multi-
center prospective cohort study, which included 3,146 patients after successful PTCA.
Patients with acute myocardial infarction (MI) were excluded. Genotyping was performed
for different polymorphisms in several candidate genes.
Results: A total of 3,146 patients (age 62.1±10.7 yrs) were followed for 10±3 months. Of
the patients 2,250 (71.5%) were male, 459 (14.6%) had diabetes and 1,459 (46.4%) had
multivessel disease. The majority was treated for stable angina. Stenting was performed
in 2,340 (74.4%) patients. Target vessel revascularisation (TVR) after the first month of
follow-up by either CABG or PTCA was necessary in 304 patients (9.7%). So far we iden-
tified an association between three polymorphism and TVR. The adrenergic beta-2
receptor and stromal cell derived factor (p=0.022, p=0.038 respectively) were associated
with increased risk of TVR. Small inducible cytokine subfamily A (eotaxin) (p=0.057 )
showed a protective association with TVR.
Conclusion: So far in this unselected large group of patients treated with PTCA, we
already identified three polymorphisms in different candidate genes that were related to
restenosis after PTCA. More genotyping is being performed. Our results can contribute
to the unravelling of the restenotic process and might provide a better risk stratification
and lead to a more tailored therapy for patients with identified increased risk of restenosis
after PTCA.
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